Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Public access defibrillators

This article was originally published in The Gray Sheet

Executive Summary

HR 3462, the Community Access to Emergency Defibrillation Act of 2001 (Community AED Act) is introduced in the House Dec. 12 by Reps. Lois Capps (D-Calif.) and John Shimkus (R-Ill.). The bill authorizes more than $55 mil. a year for five years for communities to purchase automatic external defibrillators and to establish public access to defibrillation (PAD) programs. The measure is identical to S 1275, which was introduced July 31 by Sens. Edward Kennedy (D-Mass.) and Bill Frist (R-Tenn.). Staffers are cautiously optimistic that the bill could be hotlined for floor consideration in the next few weeks. AED manufacturer Medtronic VP-Corporate Controller Gary Ellis notes that its LifePak system direct-to-consumer advertising has helped to build awareness of the condition and its risk factors...

You may also be interested in...

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts